FDA Approves Corcept Therapeutics' Lifyorli for Ovarian Cancer Treatment

The U.S. Food and Drug Administration (FDA) has officially approved Corcept Therapeutics' (NASDAQ: CORT) drug Lifyorli (relacorilant) for the treatment of ovarian cancer. The approval specifically covers the use of Lifyorli in combination with nab-paclitaxel for adult patients suffering from platinum-resistant epithelial ovarian cancer. This regulatory milestone marks a significant breakthrough for Corcept, as it introduces a new therapeutic option for a particularly difficult-to-treat form of the disease. Lifyorli works as a selective glucocorticoid receptor antagonist, designed to modulate the effects of cortisol in the body. Investors are expected to react positively to the news, as FDA approvals are primary value drivers in the biotechnology sector. The company is poised to see substantial revenue growth following the commercial launch of the treatment.

Sources:businesswire.comreuters.cominvesting.comtipranks.comstocktwits.comgurufocus.comeconomictimes.comfda.govfiercepharma.combioworld.comlasvegassun.comcancernetwork.comempr.com